^
    1d
    Refractory Pembrolizumab-Induced Myocarditis-Myositis-Myasthenia Gravis Overlap Syndrome With Concurrent Hepatitis and Thyroiditis in Endometrial Carcinoma: A Case Report. (PubMed, Cureus)
    A 77-year-old woman with stage IV serous endometrial carcinoma presented 24 days after a single dose of carboplatin, paclitaxel, and pembrolizumab, with progressive weakness, ptosis, diplopia, and respiratory compromise...She was treated with pulse corticosteroids and plasma exchange (PLEX), with rituximab added after the second session for an inadequate response. Persistent myocarditis with sustained troponin elevation prompted further escalation to abatacept and ruxolitinib...The case is distinguished by refractory disease requiring four sequential lines of immunosuppression, concurrent immune-mediated hepatitis and thyroiditis, and a seronegative myasthenia gravis profile, consistent with the more heterogeneous, non-antibody-mediated mechanisms increasingly recognized in ICI-induced disease. It informs treatment escalation in refractory cases and underscores three principles essential to managing this high-mortality syndrome: early recognition, systematic screening for all syndromic components once any one is identified, and timely escalation through multiple lines of immunosuppression when disease proves refractory.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    LRP4 (LDL Receptor Related Protein 4)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • Rituxan (rituximab) • Jakafi (ruxolitinib) • Orencia (abatacept)
    2d
    A Study of Ruxolitinib in Patients With Graft-Versus Host Disease (clinicaltrials.gov)
    P=N/A, N=395, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jakafi (ruxolitinib)
    2d
    Fibrotic marrow limiting morphologic classification in MDS/MPN with SF3B1 mutation and thrombocytosis: diagnostic implications under the ICC 2022 framework. (PubMed, Virchows Arch)
    After ruxolitinib therapy, he later developed leukocytosis and 2% circulating blasts. Repeat marrow demonstrated ≥ 15% ring sideroblasts. Retrospectively, the initial biopsy fulfills ICC 2022 criteria for MDS/MPN-SF3B1-T, highlighting the diagnostic value of genetics-integrated classification in fibrotic marrows.
    Journal
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog) • JAK2 (Janus kinase 2) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1)
    |
    SF3B1 mutation • NRAS G12
    |
    Jakafi (ruxolitinib)
    2d
    Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease (clinicaltrials.gov)
    P4, N=50, Recruiting, Novartis Pharmaceuticals | Trial primary completion date: Nov 2029 --> May 2029
    Trial primary completion date
    |
    Jakafi (ruxolitinib)
    3d
    Temozolomide and ruxolitinib combination modulates miRNA-associated regulatory networks in glioblastoma stem cells. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    Overall, our findings suggest that TMZ may induce oncogenic miRNA expression as part of an adaptive response, while ruxolitinib may counteract this effect. Targeting miRNA-mediated regulatory networks in combination with pathway inhibition may represent a promising strategy to overcome therapeutic resistance in glioblastoma.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • BCL2L11 (BCL2 Like 11) • MIR221 (MicroRNA 221) • MIR19A (MicroRNA 19a)
    |
    temozolomide • Jakafi (ruxolitinib)
    4d
    SERPINE2-mediated activation of JAK2/STAT3 facilitates NRF2 nuclear translocation and GCLC transcription to confer ferroptosis resistance and lenvatinib resistance in hepatocellular carcinoma. (PubMed, J Exp Clin Cancer Res)
    This study established the SERPINE2-JAK2/STAT3-NRF2-GCLC signaling axis as a key mechanism driving ferroptosis resistance and lenvatinib treatment failure. Targeting this axis provides a novel therapeutic strategy for overcoming lenvatinib resistance in HCC.
    Journal
    |
    JAK2 (Janus kinase 2) • STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    Lenvima (lenvatinib) • Jakafi (ruxolitinib)
    5d
    Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas (clinicaltrials.gov)
    P1, N=20, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: Apr 2026 --> Dec 2025
    Enrollment open • Trial initiation date
    |
    doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • daunorubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    5d
    Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma (clinicaltrials.gov)
    P2, N=330, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Oct 2026 --> Jun 2027
    Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    ALK positive
    |
    Jakafi (ruxolitinib) • cyclophosphamide • sirolimus
    6d
    Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma (clinicaltrials.gov)
    P1, N=60, Completed, Case Comprehensive Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    temozolomide • Jakafi (ruxolitinib)
    6d
    Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study. (PubMed, Hematology)
    Treatment strategies included supportive care, interferon, hydroxyurea, and ruxolitinib. PMF and SMF demonstrate distinct clinical phenotypes despite sharing bone marrow fibrosis as a common endpoint. The mutational landscape highlights the genetic heterogeneity of MF and underscores the importance of integrating clinical, pathological, and molecular information to improve disease characterization and guide individualized management.
    Retrospective data • Journal
    |
    JAK2 (Janus kinase 2) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CALR (Calreticulin)
    |
    ASXL1 mutation
    |
    Jakafi (ruxolitinib) • hydroxyurea
    7d
    ELRISE MF: A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib (clinicaltrials.gov)
    P3, N=324, Not yet recruiting, Takeda
    New P3 trial
    |
    Jakafi (ruxolitinib) • elritercept (KER-050)
    7d
    Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (clinicaltrials.gov)
    P4, N=10, Not yet recruiting, University of California, San Francisco | Initiation date: Jan 2026 --> Aug 2026
    Trial initiation date
    |
    5-fluorouracil • Jakafi (ruxolitinib) • hydroxychloroquine • roflumilast • tofacitinib • Cosentyx (secukinumab) • Dupixent (dupilumab) • Ilumya (tildrakizumab-asmn)